Hence, the results mentioned above may not only indirectly prove that variations in the tumor m6A modification mode are key factors mediating the clinical response to anti–PD-1/PD-L1 immunotherapy but also confirm the value of m6Ascore in forecasting the outcome of immunotherapy. The gene discussed is PDCD1; the disease is neoplasm.